Related Experiment Video
Updated: Sep 13, 2025
Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs
Published on: January 27, 2023
Application of gene therapy in osteoarthritis
You Li1, Biao Li1,2, Andras Nagy2,3,4
1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Canada.
Abstract:
Osteoarthritis (OA) is a leading cause of pain and disability globally,characterized by progressive cartilage degeneration, subchondralbone remodeling, and synovial inflammation. Current treatmentsprimarily offer symptomatic relief without addressing the underlyingdisease mechanisms or halting progression. Gene therapy hasemerged as a promising strategy to target the molecular drivers ofOA by modulating key pathways involved in inflammation, tissuedegeneration, and pain. This review summarizes recent advancesin OA gene therapy, including anti-inflammatory approachestargeting IL-1β and IL-10, as well as regenerative strategiesleveraging TGF-β1 and FGF-18. Preclinical and early clinicalstudies have shown encouraging results in both symptom reliefand cartilage preservation. However, significant challengesremain, including vector safety, immune responses, and thecomplex, heterogeneous nature of OA that complicates treatmentresponse. The integration of precision medicine with improved genedelivery platforms and combinatorial therapeutic strategies holdsstrong potential to overcome these limitations. Collectively, theseinnovations may accelerate the development of disease-modifyingosteoarthritis drugs (DMOADs) and provide long-term, effectivetherapeutic options for patients.
Insights
Gene therapy offers a promising approach to treat osteoarthritis (OA) by targeting underlying disease mechanisms. Advances in gene therapy show potential for cartilage preservation and pain relief, paving the way for disease-modifying osteoarthritis drugs (DMOADs).
Area of Science:
- Orthopedics and Regenerative Medicine
- Molecular Biology and Genetics
Background:
- Osteoarthritis (OA) is a major global cause of pain and disability, characterized by cartilage degeneration, bone remodeling, and inflammation.
- Current OA treatments provide only symptomatic relief, failing to address disease progression or underlying mechanisms.
- Gene therapy presents a novel strategy to target molecular drivers of OA, offering potential disease modification.
Purpose of the Study:
- To review recent advancements in gene therapy for osteoarthritis.
- To explore anti-inflammatory and regenerative gene therapy approaches for OA.
- To discuss challenges and future directions in OA gene therapy development.
Main Methods:
- Review of preclinical and early clinical studies on gene therapy for OA.
- Focus on anti-inflammatory strategies targeting cytokines like IL-1β and IL-10.
- Examination of regenerative strategies utilizing growth factors such as TGF-β1 and FGF-18.
Main Results:
- Gene therapy approaches have demonstrated encouraging preclinical and early clinical results.
- Evidence suggests potential for both symptom relief and cartilage preservation in OA.
- Key challenges include vector safety, immunogenicity, and the heterogeneity of OA.
Conclusions:
- Gene therapy holds significant promise for developing disease-modifying osteoarthritis drugs (DMOADs).
- Precision medicine, improved gene delivery, and combination therapies are crucial for overcoming current limitations.
- Future innovations could lead to long-term, effective OA treatments.
